Should You Buy Abbott Labs Stock Hand Over Fist Before July 16?

Abbott Laboratories (NYSE: ABT) reports second-quarter net connected July 16, and immoderate investors are trying to find whether to bargain the banal earlier the study is released oregon hold for the results.

But you can't marque a due determination astir this without archetypal knowing what drives Abbot's growth. So let's instrumentality a person look.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

The diversification origin

Unlike immoderate healthcare companies that beryllium heavy connected a azygous blockbuster product, Abbott operates crossed 4 large concern segments: aesculapian devices, diagnostics, nutrition, and established pharmaceuticals. That diversification has helped the institution stay resilient done changing healthcare and economical environments for astir 50 years.

Now the company's largest maturation motor is its aesculapian instrumentality business. During Q1, aesculapian instrumentality gross reached astir $5.5 billion, accounting for astir fractional of Abbott's full sales. Within that segment, diabetes attraction continues to basal out.

Abbott's FreeStyle Libre continuous glucose monitoring level generated astir $2 cardinal successful quarterly sales. Libre has go 1 of the astir wide utilized glucose-monitoring systems successful the world, with much than 7 cardinal users crossed implicit 60 countries. This is not insignificant arsenic diabetes remains 1 of the fastest-growing chronic diseases globally.

The International Diabetes Federation's information bespeak much than 589 cardinal adults worldwide are presently surviving with diabetes, a fig expected to transcend 850 cardinal by 2050. As adoption of continuous glucose monitoring exertion expands, Abbott has a important accidental to proceed increasing this franchise.

Heart repair income are expanding

Abbot's cardiovascular concern is besides contributing, with its structural bosom conception generating astir $578 cardinal successful Q1 revenue. Products specified arsenic MitraClip and TriClip are helping the institution seizure a increasing stock of the minimally invasive bosom repair market, which analysts expect to grow importantly implicit the adjacent decennary arsenic populations age.

Beyond devices, Abbott besides continues to make dependable gross from diagnostics and nutrition. Its diagnostics conception produced astir $2.1 cardinal successful Q1 sales, portion nutrition generated astir $2 billion. Brands specified arsenic Ensure, Glucerna, Pedialyte, and Similac proceed providing recurring gross streams that assistance offset fluctuations elsewhere successful the business.